These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28914644)

  • 1. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice.
    Silva IP; Long GV
    Curr Opin Oncol; 2017 Nov; 29(6):484-492. PubMed ID: 28914644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
    Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
    Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetic and immunotherapeutic targets in metastatic melanoma.
    Melis C; Rogiers A; Bechter O; van den Oord JJ
    Virchows Arch; 2017 Aug; 471(2):281-293. PubMed ID: 28357489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
    Zhu Z; Liu W; Gotlieb V
    Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma.
    da Silveira Nogueira Lima JP; Georgieva M; Haaland B; de Lima Lopes G
    Cancer Med; 2017 Jun; 6(6):1143-1153. PubMed ID: 28463413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.
    Lau PK; Ascierto PA; McArthur G
    Curr Opin Immunol; 2016 Apr; 39():30-8. PubMed ID: 26765776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
    Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
    Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma.
    Christiansen SA; Khan S; Gibney GT
    Cancer J; 2017; 23(1):59-62. PubMed ID: 28114256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Systemic treatment of inoperable metastasized malignant melanoma].
    Gutzmer R; Rauschenberg R; Meier F
    Hautarzt; 2016 Jul; 67(7):529-35. PubMed ID: 27164828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Therapy and Immunotherapy for Melanoma in Japan.
    Namikawa K; Yamazaki N
    Curr Treat Options Oncol; 2019 Jan; 20(1):7. PubMed ID: 30675668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Gogas H
    Expert Rev Anticancer Ther; 2020 Jan; 20(1):53-62. PubMed ID: 31903803
    [No Abstract]   [Full Text] [Related]  

  • 13. The Systemic Management of Advanced Melanoma in 2016.
    Heppt MV; Dietrich C; Graf SA; Ruzicka T; Tietze JK; Berking C
    Oncol Res Treat; 2016; 39(10):635-642. PubMed ID: 27710977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic use of anti-CTLA-4 antibodies.
    Blank CU; Enk A
    Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for melanoma.
    Cuevas LM; Daud AI
    Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Targets for the Treatment of Melanoma.
    Ambrosi L; Khan S; Carvajal RD; Yang J
    Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.
    Ascierto PA; Flaherty K; Goff S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():751-758. PubMed ID: 30231371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of targeted therapy for melanoma in the immunotherapy era.
    Sullivan RJ
    Semin Cutan Med Surg; 2018 Jun; 37(2):112-119. PubMed ID: 30040088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.